Home Tags Kadcyla

Tag: Kadcyla

Ado-trastuzumab emtansine Approved for the Treatment of Early Breast Cancer

In early May 2019, the United States Food and Drug Administration (FDA) approved ado-trastuzumab emtansine (Kadcyla®, Genentech/Roche; T-DM1) for the adjuvant treatment of patients...

Four Ways to Show Nonobviousness of ADC Inventions

As research continues to progress and the scientific community’s appreciation for the power of ADCs has grown, so have the numbers. FDA has now approved at least four ADCs, and hundreds more are in development. The number of patent applications has also grown, with the U.S. Patent and Trademark Office (USPTO) publishing over two hundred patent applications with claims to ADC inventions in the last two years alone.

Antibody-Drug Conjugates at the 59th American Society of Hematology Annual...

This year, in Atlanta, the South's largest and most vibrant city, the 59th annual meeting and exposition of the American Society of Hematology, to...

Antibody-drug Conjugates: Technologies and Global Markets

Less than 3 decades old, antibody-drug conjugate or ADC-technology is a relatively new.  Due to many technological advances, recognition of appropriate target antigens, success...

PEGS Boston 2017: Catalent Biologics Advances Antibody-Drug Conjugate Development

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that...

Improving Outcomes in the Treatment of Breast Cancer (Video)

Over the last 25 years, there has been an explosion of new and vitally important, anticancer drugs.The development of these promising new therapeutic agents...

Anti-HER2 ADC SYD985 to be Evaluated in Expanded Cohort of HER2+...

Dutch pharmaceutical company Synthon Biopharmaceuticals has initiated the second part of an ongoing phase I clinical trial with its investigational anti-HER2 antibody-drug conjugate or ADC,...

Clinical Updates Confirming Advances and Meaningful Benefits for Patients

Earlier this year, during the meetings of the American Association for Cancer Research (AACR), held April 16-20 in New Orleans, LA, and the Protein...

Growing Drug Development Outsourcing Expected to Increase Demand for Antibody-drug Conjugates

A recent research report published by Technavio, a leading global technology research and advisory company, confirms that the global antibody-drug conjugates (ADC) market will grow...

Biparatopic HER2-targeting Antibody-drug Conjugate Demonstrates Potent Antitumor Activity

HER2-targeted therapies have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of breast cancer.  Being overexposed in 20-25% of human breast cancers...

FEATURED RESOURCES